Randomized Blinded Phase III Assessment of Second or Third-Line Chemotherapy With Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced Non-Small Cell Lung Cancer and With at Least One Measurable Lung Lesion
Phase of Trial: Phase III
Latest Information Update: 14 Dec 2017
At a glance
- Drugs Docetaxel (Primary) ; Plinabulin (Primary)
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms DUBLIN-3
- Sponsors BeyondSpring Pharmaceuticals
- 14 Dec 2017 Interim anti-cancer efficacy data is expected in mid-2018, according to a BeyondSpring Pharmaceuticals media release.
- 14 Dec 2017 Results published in the BeyondSpring Pharmaceuticals Media Release
- 09 Nov 2017 According to a BeyondSpring Pharmaceuticals media release, interim data from this trial are expected in mid-2018.